Prestige Consumer Healthcare sets November 5 results for Prestige Consumer Healthcare stock

Prestige Consumer Healthcare announced on October 14, 2026 that it will publish fiscal 2027 second-quarter and first-half results on November 5, 2026 before the market opens, with its conference call scheduled for 8:30 a.m. ET, according to StockTitan. Prestige Consumer Healthcare was trading at EUR 43.80 at Lang & Schwarz on October 20, 2026 at 10:04 p.m. CEST.

Revenue growth sets the backdrop

The next report will follow fiscal 2027 first-quarter revenue of USD 265.71 million, a 6.50 percent increase from USD 249.50 million a year earlier. Benzinga reported that adjusted diluted earnings per share rose to USD 0.98 from USD 0.95, while adjusted free cash flow reached USD 83.70 million.

Management raised fiscal 2027 revenue guidance to USD 1.29 billion to USD 1.315 billion and retained its organic growth outlook of 1.00 percent to 3.00 percent. The guidance range includes contributions from the Breathe Right and Locorium Health acquisitions, making the November report a test of integration and demand timing.

US listing remains the market anchor

On the NYSE, the stock was last at USD 49.36 on October 20, 2026 at 3:59 p.m. EDT. Its 52-week range was USD 42.62 to USD 71.07 on October 20, 2026, putting the US quote USD 6.74 above the low and USD 21.71 below the high.

Prestige Consumer Healthcare carried a market capitalization of USD 2.3 billion on October 20, 2026. The company operates in consumer healthcare, with brands including Dramamine, Tagamet, Breathe Right and Clear Eyes. Its first-quarter adjusted gross margin was about 55.00 percent, down 1.20 percentage points from the prior year, while full-year adjusted gross margin guidance was just above 57.00 percent, according to ScanX.

November 5 is the next checkpoint

The November 5 release will provide the next dated operating update, including second-quarter and first-half revenue, earnings and cash flow. The company has guided second-quarter revenue to USD 328 million to USD 331 million and adjusted diluted earnings per share to USD 1.06 to USD 1.08, according to Benzinga. The reported figures will also indicate how much retailer order timing affects the quarter.

Stock position and reporting date

For investors, the key contrast is between the 6.50 percent first-quarter revenue increase and the 1.20 percentage-point gross-margin decline. The November release is scheduled before the market opens and the conference call follows at 8:30 a.m. ET. The further course of trading is shown by the continuously updated real-time quote of Prestige Consumer Healthcare stock.

Market context: Market report S&P 500.

More news and analyses on Prestige Consumer Healthcare stock